Matthew J Wakefield
Overview
Explore the profile of Matthew J Wakefield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
5900
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nesic K, Krais J, Vandenberg C, Wang Y, Patel P, Cai K, et al.
medRxiv
. 2023 Mar;
PMID: 36993400
splice isoforms Δ11 and Δ11q can contribute to PARP inhibitor (PARPi) resistance by splicing-out the mutation-containing exon, producing truncated, partially-functional proteins. However, the clinical impact and underlying drivers of exon...
12.
Veneziani A, Scott C, Wakefield M, Tinker A, Lheureux S
Ther Adv Med Oncol
. 2023 Mar;
15:17588359231157644.
PMID: 36872947
Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of 'synthetic lethality' is exploited by PARPi in tumors with defects in...
13.
Ho G, Kyran E, Bedo J, Wakefield M, Ennis D, Mirza H, et al.
Cancer Res
. 2022 Oct;
82(23):4457-4473.
PMID: 36206301
Significance: Genomic analyses and preclinical models of ovarian carcinosarcoma support the conversion theory for disease development and indicate that microtubule inhibitors could be used to suppress EMT and stimulate antitumor...
14.
Kondrashova O, Ho G, Au-Yeung G, Leas L, Boughtwood T, Alsop K, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-18.
PMID: 35100705
Purpose: The ALLOCATE study was designed as a pilot to demonstrate the feasibility and clinical utility of real-time targeted molecular profiling of patients with recurrent or advanced ovarian cancer for...
15.
Nesic K, Kondrashova O, Hurley R, McGehee C, Vandenberg C, Ho G, et al.
Cancer Res
. 2021 Jul;
81(18):4709-4722.
PMID: 34321239
In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene are established drivers of defective homologous recombination and are emerging biomarkers of PARP inhibitor (PARPi) sensitivity. promoter methylation...
16.
Hurley R, McGehee C, Nesic K, Correia C, Weiskittel T, Kelly R, et al.
NAR Cancer
. 2021 Jul;
3(3):zcab028.
PMID: 34316715
Acquired PARP inhibitor (PARPi) resistance in - or -mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. is a less commonly studied ovarian cancer susceptibility...
17.
Grohmann C, Walker F, Devlin M, Luo M, Chueh A, Doherty J, et al.
Cell Death Dis
. 2021 Mar;
12(3):268.
PMID: 33712556
Targeting cell division by chemotherapy is a highly effective strategy to treat a wide range of cancers. However, there are limitations of many standard-of-care chemotherapies: undesirable drug toxicity, side-effects, resistance...
18.
Kommoss F, Cheasley D, Wakefield M, Scott C, Campbell I, Gilks C, et al.
Histopathology
. 2020 Nov;
78(4):640-642.
PMID: 33151585
No abstract available.
19.
Kang E, Cheasley D, Lepage C, Wakefield M, da Cunha Torres M, Rowley S, et al.
Mod Pathol
. 2020 Jul;
34(1):194-206.
PMID: 32724153
TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimized immunohistochemistry (IHC) for TP53 has been established as a proxy for the...
20.
Sanij E, Hannan K, Xuan J, Yan S, Ahern J, Trigos A, et al.
Nat Commun
. 2020 May;
11(1):2641.
PMID: 32457376
Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cancer (HGSOC). Here, we demonstrate CX-5461, the first-in-class inhibitor of RNA...